Problems associated with a long-term application of L-dopa to treat Parkinsons disease, have prompted interest in developing alternative therapeutic strategies. Parkinsons disease is a suitable candidate for neurological gene therapy, given our knowledge of the functional anatomy of the striato-nigral system. Recently, much effort was devoted to the administration of trophic factors to injured neurons, especially using glial cell line-derived factor (DGNF). Various aspects of this approach are discussed in this study.
|Published - Dec 2001